SCHEMBL4740524

SCHEMBL4740524

CO/C=C(\C(=O)O)c1ccccc1Oc1cc(Cl)ncn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
HTT P42858 2/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ATM Q13315 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
MAPT P10636 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
LMNA P02545 2/20 0.34
RORB Q92753 2/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713694 1.00 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL29391212 1.00 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL713692 1.00 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL31493947 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL709624 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL1223741 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL2996165 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL29657093 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL29391047 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL713693 0.89 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2537832-B1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE CHONGQING UNISPLENDOUR CHEM CO (CN) 2015-08-12 EP claimed
EP-1399427-A1 PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF Syngenta Limited (GB) 2004-03-24 EP claimed
WO-2002100837-A1 PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF SYNGENTA LIMITED (GB) 2002-12-19 WO claimed
EP-3004066-B1 PROCESS FOR PREPARING 4,6-BIS(ARYLOXY)PYRIMIDINE DERIVATIVES CHEMINOVA AS (DK) 2018-04-11 EP disclosed
US-9643935-B2 Process for preparing 4,6-BIS (aryloxy) pyrimidine derivatives CHEMINOVA A/S (DK) 2017-05-09 US disclosed
US-20160137612-A1 PROCESS FOR PREPARING 4,6-BIS (ARYLOXY) PYRIMIDINE DERIVATIVES CHEMINOVA A/S (DK) 2016-05-19 US disclosed
EP-2537832-B1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE CHONGQING UNISPLENDOUR CHEM CO (CN) 2015-08-12 EP disclosed
EP-2537832-B1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE CHONGQING UNISPLENDOUR CHEM CO (CN) 2015-08-12 EP disclosed
EP-2076498-B1 PREPARATION OF AZOXYSTROBIN SYNGENTA LTD (GB) 2015-02-25 EP disclosed
EP-2537832-A4 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE CHONGQING UNISPLENDOUR CHEM CO (CN) 2014-08-06 EP disclosed
EP-2537832-A1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE Chongqing Unisplendour Chemical Co., Ltd. (CN) 2012-12-26 EP disclosed
EP-2537832-A1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE Chongqing Unisplendour Chemical Co., Ltd. (CN) 2012-12-26 EP disclosed
WO-2012037764-A1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE 重庆紫光化工股份有限公司 (CN) 2012-03-29 WO disclosed
WO-2012037764-A1 METHOD FOR PREPARING (E)-METHYL 2-[2-(6-CHLOROPYRIMIDIN-4-YLOXY)PHENYL]-3-METHOXYACRYLATE 重庆紫光化工股份有限公司 (CN) 2012-03-29 WO disclosed
WO-2008093325-A2 POLYMORPHS OF 3-(E)-2-{2-[6-(2-CYANOPHENOXY) PYRIMIDIN-4-YLOXY]PHENYL}-3-METHOXYACRYLATE MAKHTESHIM CHEMICAL WORKS LTD. (IL) 2008-08-07 WO disclosed
EP-1891020-A2 PROCESSES FOR THE PREPARATION OF AZOXYSTROBIN USING DABCO AS A CATALYST AND NOVEL INTERMEDIATES USED IN THE PROCESSES Syngenta Limited (GB) 2008-02-27 EP disclosed
WO-2006114572-A2 PROCESSES FOR THE PREPARATION OF AZOXYSTROBIN USING DABCO AS A CATALYST AND NOVEL INTERMEDIATES USED IN THE PROCESSES SYNGENTA LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137612-A1 PROCESS FOR PREPARING 4,6-BIS (ARYLOXY) PYRIMIDINE DERIVATIVES NUDT1, UMPS, DPYD ALDH1A1 1125/4885SMN1; SMN2 3435/4885MEN1 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.